Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-018-0644-2
Abstract: The novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry powder inhaler (MDPI) (AirDuo RespiClick®) was recently approved in the USA for twice-daily treatment of asthma in patients aged ≥ 12 years. This inhaled corticosteroid (ICS) and long-acting… read more here.
Keywords: fluticasone propionate; propionate salmeterol; salmeterol mdpi; mdpi ... See more keywords
Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: A randomized, controlled, dose-ranging study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Asthma"
DOI: 10.1080/02770903.2016.1242137
Abstract: ABSTRACT Objective: Evaluate fluticasone propionate (Fp) using a novel, inhalation-driven, multidose dry powder inhaler (MDPI) in patients with severe persistent asthma, versus placebo MDPI and Fp dry powder inhaler (DPI). Methods: Patients with persistent asthma… read more here.
Keywords: patients severe; safety; mdpi; fluticasone propionate ... See more keywords
Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
Sign Up to like & getrecommendations! Published in 2017 at "Allergy and asthma proceedings"
DOI: 10.2500/aap.2017.38.4069
Abstract: BACKGROUND A novel, inhalation-driven, multidose dry powder inhaler (MDPI) has been developed, which allows for lower doses of fluticasone propionate (Fp) and Fp/salmeterol (FS) for the treatment of patients with asthma. OBJECTIVE This phase III,… read more here.
Keywords: end points; asthma; fluticasone propionate; mdpi ... See more keywords